SANTA ANA, Calif., Dec. 16, 2025 — Synergetics.ai, pioneer of the Agent Economy and creator of the world’s first AI Agent Wallet and decentralized Agent Commerce infrastructure, today announced Taisu Ventures’ strategic investment in its Seed Round token fundraise. The funding will accelerate the SGTX token launch, ecosystem expansion, and upcoming token generation event (TGE).
Figure 1 Taisu Ventures invests in Synergetics.ai Token fundraise
Figure 2 Synergetics.ai powers the Agent Economy
The SGTX token powers payments, staking, governance, and commerce across the Synergetics Agent Network. It enables trustless settlement, usage-based billing, and seamless transactions for agents, creators, enterprises, digital twins, and automated systems in industries like telecom, e-commerce, healthcare, banking, and entertainment.
Key SGTX utilities include:
Agent-to-agent payments and micro-transactions.
Staking for network security and rewards.
Governance for protocol upgrades.
Commerce in the Agent Marketplace.
Takashi Hayashida, Managing Partner at Taisu Ventures, said: “Synergetics.ai is building essential infrastructure for agent-to-agent commerce at scale, an inevitable evolution of the AI economy. We believe SGTX will become foundational for how autonomous agents transact globally. Our investment reflects conviction in the technology and team.”
Synergetics.ai CEO Raghu Bala added: “The AI Agent Economy is here, and it needs a new transactional fabric. SGTX is that fabric. Taisu Ventures’ Web3 expertise makes them an ideal partner as we deliver the world’s first end-to-end Agent Commerce platform.”
The investment supports expansion of the Agent Marketplace, development of patented protocols like AgentTalk for secure multi-agent communication, and adoption of AgentWallet for enterprise workflows, digital twins, and real-time collaboration.
About Taisu Ventures Taisu Ventures is a global early-stage firm focused on Web3 infrastructure, digital assets, and frontier technologies. Learn more atwww.taisu.io.
About Synergetics.ai Synergetics.ai enables creation, orchestration, deployment, and monetization of autonomous AI agents via AgentTalk protocol, AgentWallet, Agent Marketplace, and AgentWorks suite. Visitwww.synergetics.ai.
Company accelerates investments in Agent Bricks, Lakebase and Databricks Apps to power Data Intelligent Applications
SAN FRANCISCO, Dec. 16, 2025 — Databricks, the Data and AI company, today announced it is raising a >$4 billion Series L investment, valuing the company at $134 billion. Additionally, the company crossed a $4.8 billion revenue run-rate during its Q3, growing >55% year over year, including >$1 billion revenue run-rate from its Data Warehousing business and >$1 billion revenue run-rate from its AI products — all while delivering positive free cash flow over the last 12 months.
The parallel rise of vibe coding and generative AI is accelerating the development of Data Intelligent Applications in the enterprise. Databricks will use this new capital to help customers build AI apps and agents on their proprietary data, leveraging Lakebase as the system of record, Databricks Apps as the user experience layer, and Agent Bricks to power multi-agent systems.
The round was led by Insight Partners, Fidelity Management & Research Company, and J.P. Morgan Asset Management with additional participation from Andreessen Horowitz, funds and accounts managed by BlackRock, funds managed by Blackstone (“Blackstone”), Coatue, GIC, MGX, NEA, Ontario Teachers Pension Plan, Robinhood Ventures, accounts advised by T. Rowe Price Associates, Inc., Temasek, Thrive Capital and Winslow Capital. This new investment builds on Databricks’ accelerating financial results and underscores the company’s vision to make data and AI accessible to all organizations.
Databricks’ Financial Momentum This funding follows continued strong momentum across Databricks’ business, including:
Surpassing $4.8 billion revenue run-rate, growing >55% year over year.
Continuing to achieve positive free cash flow over the last 12 months.
Achieving >$1 billion revenue run-rate for its AI products.
In its first six months, Lakebase already has thousands of customers and is growing revenue at twice the pace of its Data Warehousing product.
Achieving >$1 billion revenue run-rate for its Data Warehousing product in less than four years from general availability.
Net retention rate sustaining >140%.
>700 customers consuming at over $1 million annual revenue run-rate.
The Rise of Data Intelligent Applications Databricks’ Series L funding will advance product development across three strategic products, helping customers build Data Intelligent Applications.
Lakebase is the first serverless Postgres database purpose-built for the age of AI.
Databricks Apps offers world-class speed and security to build and deploy data and AI applications.
Agent Bricks makes it easy for organizations to build and scale high-quality agents on their data.
In addition to fueling its growth, this capital is expected to be used to provide liquidity for employees. The investment is also expected to support future AI acquisitions and deepen AI research.
“Enterprises are rapidly reimagining how they build intelligent applications, and the convergence of generative AI with new coding paradigms is opening the door to entirely new workloads. With this investment, we’re deepening our commitment to help every organization innovate with AI on their own data,” said Ali Ghodsi, co-founder and CEO of Databricks. “By anchoring transactional data in Lakebase, delivering intuitive experiences through Databricks Apps, and enabling advanced multi-agent systems with Agent Bricks, we’re giving customers a unified foundation to build trusted, high-performance Data Intelligent Applications at scale.”
“Our continued investment in Databricks reflects our deep conviction in their extraordinary momentum today and their ambitious vision for the future,” said John Wolff, Managing Director at Insight Partners. “Databricks leads the way in turning AI innovation into enterprise impact. We’re thrilled to deepen our investment in a team that continues to pair strong financial performance with real customer results, setting the standard for how AI creates value for businesses. Databricks is just getting started.”
About Databricks Databricks is the Data and AI company. More than 20,000 organizations worldwide — including adidas, AT&T, Bayer, Block, Mastercard, Rivian, Unilever, and over 60% of the Fortune 500 — rely on Databricks to build and scale data and AI apps, analytics and agents. Headquartered in San Francisco with 30+ offices around the globe, Databricks offers a unified Data Intelligence Platform that includes Agent Bricks, Lakeflow, Lakehouse, Lakebase and Unity Catalog. To learn more, follow Databricks on LinkedIn, X, YouTube, and Instagram.
Led by Sea Court Capital, investment round to foster innovation, transform medicine storage
LOS ANGELES, Dec. 16, 2025 — Ember LifeSciences, Inc., a leading provider of revolutionary cold chain technology, today announced a $16.5 million Series A funding round, led by Sea Court Capital, with participation from Cardinal Health, Carrier Ventures and other influential investors, including former U.S. Secretary of State Mike Pompeo. The round underscores strong investor confidence in Ember LifeSciences’ ability to redefine global medicine distribution through its proprietary temperature control technology.
Ember Cube 2
The global pharmaceutical cold chain ecosystem faces $35 billion in financial loss each year due to temperature excursions, and 330 billion pounds of waste are generated annually from single-use cold chain packaging.
“Our breakthrough cold chain technology ensures life-saving medicines reach their destination safely, reliably and sustainably,” said Clay Alexander, founder and CEO of Ember LifeSciences. “This investment marks a major step forward in advancing the future of healthcare, allowing us to accelerate our next-generation product development, and expand into global markets.”
This funding will progress Ember LifeSciences’ innovation pipeline, including the launch of the Ember Cube 2, which builds off learnings captured from the first-generation Ember Cube, a first-of-its-kind digital shipping box that features cloud-based temperature reporting, GPS location tracking and return-to-sender technology.
Further optimized for scale and efficiency, the second-generation Ember Cube serves organizations shipping high volumes of temperature-sensitive therapies using a version of the Ember Cube with highly efficient vacuum insulation and proprietary bio-based organic phase change material (PCM) packs for thermal control. By evolving into a configurable passive platform, this new model will extend to broader healthcare networks and enable patient-focused adoption across the supply chain.
The $16.5 million investment will also support high volume deployments with domestic customers as the company prepares to introduce patient-focused products that enhance medicine storage and transportation at the consumer level.
Ember LifeSciences’ cold chain technology is rapidly being adopted by leading pharmaceutical distributors, specialty and infusion pharmacies and testing laboratories including CVS Health, Chartwell and USADA.
About Ember LifeSciences Ember LifeSciences initially launched as an offshoot of Ember Technologies’ “Ember,” the design-led temperature control brand and maker of the award-winning temperature control mug, which has surpassed half a billion dollars in total sales to date. Ember LifeSciences seeks to redefine global medicine distribution through leveraging Ember’s proprietary temperature control technology to improve the way we transport life-saving medicines and vaccines around the world. To learn more about Ember LifeSciences, visit emberlifesciences.com.
SILVER SPRING, Md., Dec. 16, 2025 — The TSC Alliance Endowment Fund, a supporting organization of the TSC Alliance, has invested in Aeovian Pharmaceuticals as part of their Series B financing in support of their Phase 2 trial of AV078, a first-in-class CNS-penetrant selective mTORC1 inhibitor in tuberous sclerosis complex (TSC).
“This equity stake is in line with the TSC Alliance Endowment Fund investment policy, which allows for investments in venture capital and private equity that are directly related to advancing the TSC Alliance mission of catalyzing new treatments and driving research toward a cure,” shared Rita DiDomenico, TSC Alliance Endowment Fund Chair. “Any earnings of this investment will go right back into fulfilling the mission of the organization.”
In 2018, the TSC Alliance partnered with Aeovian Pharmaceuticals by co-funding research through the TSC Preclinical Consortium. This marked a significant step towards the development of innovative mTORC1-specific inhibitors for TSC, particularly in addressing TSC-associated epilepsy. mTORC1 is a protein complex involved in cell growth and proliferation, known to play a pivotal role in TSC pathology. The TSC Preclinical Consortium provides a screening platform to identify lead clinical drug candidates through a systematic testing process in robust and reproducible models of TSC. Since 2016, the Preclinical Consortium has worked with 27 industry partners screening 97 compounds.
“AV078 represents the first drug candidate developed using the TSC Preclinical Consortium as the preclinical efficacy engine throughout the lead development processto identify a novel clinical candidate,” said Steven L. Roberds, PhD, Chief Scientific Officer at the TSC Alliance. “We are thrilled our early investment to create the TSC Preclinical Consortium and ongoing partnership has helped enable Aeovian’s groundbreaking work with AV078.”
Following positive results in the first mouse study in 2018, Aeovian developed improved clinical candidates in partnership with the Preclinical Consortium over the next three years. From 2024 to 2025, AV078 completed Phase 1 testing in healthy volunteers.
“Our collaboration with the TSC Preclinical Consortium was instrumental in identifying and advancing AV078,” said Allison J. Hulme, Ph.D. President & CEO, Aeovian Pharmaceuticals. “The Consortium’s rigorous and disease-relevant models allowed us to rapidly evaluate selectivity, CNS penetration, and efficacy, giving us the confidence to move AV078 into clinical development. This partnership was critical in accelerating our path to Phase 2 trials.”
Aeovian Pharmaceuticals will be moving into Phase 2 clinical trials of AV078. Information on the trial can be found at www.aeovian.com.
About Aeovian Pharmaceuticals
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted and highly selective small molecules that restore cellular metabolic quality control by inhibiting mTORC1 or CD38. The company’s lead candidate, AV078, is a first-in-class CNS-penetrant selective mTORC1 inhibitor currently in Phase 2 development for refractory epilepsy associated with tuberous sclerosis complex (TSC), a rare genetic disorder driven by hyperactive mTORC1 signaling. Aeovian has also developed a proprietary library of potent, highly selective inhibitors with the potential to address multiple rare and age-related diseases. For more information, visit www.aeovian.com.
About the TSC Alliance Endowment Fund
The TSC Alliance Endowment Fund is a separate fiduciary organization specifically chartered to receive gifts that will be invested to generate an income stream that will help fulfill the mission of the TSC Alliance. The Endowment Fund ensures a permanent source of funding to better serve families touched by TSC through research, family services, and education. For more information, visit tscalliance.org/endowment.
About the TSC Alliance
The TSC Alliance is an internationally recognized nonprofit that improves quality of life for everyone affected by tuberous sclerosis complex by catalyzing new treatments, driving research toward a cure and expanding access to lifelong support. For more information, visit tscalliance.org.
Contact Dan Klein Senior Director, Communications TSC Alliance (301) 562-9890 [email protected]
System is a Public Benefit Corporation that is building the System Graph, a quantitative model of the world as one interconnected system.
The Wellcome Trust, a global charitable foundation supporting science and health, announced it has made a $6.5M program-related investment (PRI) in System. This is one of the first PRIs awarded to public interest technology by the foundation.
This program-related investment into the company will ensure that System has the necessary resources to release the System Graph into the commons, develop open-source tools for researchers, and organize events and build a global community of systems thinkers.
System’s status as a Public Benefit Corporation (PBC) is further solidified: under the terms of the agreement with Wellcome, System may not amend its charter in a way that materially changes its mission without Wellcome’s approval and commits to remaining a PBC for five years following the PRI.
NEW YORK, Dec. 16, 2025 — System, a Public Benefit Corporation developing a systems-based approach to organize the world’s data and knowledge, announced today it has been awarded a $6.5M investment from Wellcome.
“Wellcome’s funding ensures that our focus and mission as a Public Benefit Corporation is durable and sustainable”, said Adam Bly, Founder and CEO of System. “This program-related investment will be instrumental in driving systems-based research, policy, and solutions across the world.”
From Silos to Systems: Helping Anyone See and Solve Anything as a System The biggest challenges faced by humanity — from COVID to climate change — are systemic, yet data and knowledge are organized into silos, such as discipline (e.g. health and environment) or scale (e.g. molecular and epidemiological). This limits the abilities of leaders, researchers, and citizens to reliably predict outcomes, make decisions, mitigate risks — and improve the state of the world.
To address this challenge, System is developing the System Graph, a platform that leverages state-of-the-art LLMs, advanced graph technology, complexity science, and causal inference techniques to produce a model of the world as one unified whole, built from millions of rich, quantitative relationships that cut across sources and fields.
“There are vast collections of evidence that we use to tackle global health challenges such as mental health, infectious diseases, and the effects of climate on our health”, said Isabel Fletcher, Technology Manager at Wellcome. “However, this data is often fragmented, hindering important research. Wellcome’s support for System will help connect and co-ordinate this knowledge and inform health policy at scale, ultimately improving lives around the world.”
$6.5M to Advance Systems-Based Thinking, Research, and Policy Wellcome’s funding will support System’s mission in three meaningful ways.
It will first help the team provide free and open access to the System Graph for non-commercial use. This will ensure that researchers, scholars, policymakers, and journalists have access to data informing their thinking and decision-making.
System will develop open-source tools to generate living, evidence-based systems maps for any topic in the System Graph, and make data available to download for research, analysis, and visualization. There will be a strong initial focus on public health and biomedical research.
Lastly, System will use the funds to host an annual conference on systems-based solutions to the world’s greatest challenges.
Reimagining Public Interest Partnerships for AI System’s status as a Public Benefit Corporation is reinforced by this agreement. System has pledged to maintain its PBC status for the next five years. In addition, the company may not amend its charter in a way that materially alters its public benefit mission, without Wellcome’s approval.
System is committed to open data and open science. It guarantees free and open access to data, promotes the scientific method, and supports education and outreach initiatives to encourage systems literacy in society. The organization will start releasing snapshots of the System Graph into the commons in 2026.
About System System builds knowledge infrastructure to transform decision-making from silos to systems — starting in healthcare. System’s APIs are used today by leading healthcare providers in the US and Europe to power groundbreaking clinical decision support systems (CDSS). At the core of System is the System Graph, a patented, large-scale, statistical graph of the world modeled as one interconnected system, based on trusted sources of evidence that are updated daily. System Inc. is a Public Benefit Corporation committed to advancing systems thinking in the world.
About Wellcome Wellcome supports science to solve the urgent health challenges facing everyone. We support discovery research into life, health and wellbeing, and we’re taking on three worldwide health challenges: mental health, infectious disease and climate and health.
Das Unternehmen sicherte sich 47 Millionen US-Dollar durch Verlängerungsrunden der Serie A unter der Leitung von Legend Capital und Meituan Long-Z Investment mit starker Unterstützung sowohl von neuen Investoren als auch von bestehenden Unterstützern
Erlöse zur Förderung von zwei differenzierten und äußerst wettbewerbsfähigen ADC-Programmen in globalen Phase-I-Studien
Die Finanzierung wird die weitere Entwicklung von ADC- und multispezifischen Antikörperplattformen unterstützen, die darauf abzielen, kritische Einschränkungen bestehender biologischer Therapeutika zu überwinden
SHANGHAI, 16. Dezember 2025 — Allink Biotherapeutics, Inc. (AllinkBio), ein Biotechnologieunternehmen im klinischen Stadium, das sich auf die Entwicklung fortschrittlicher Antikörper-Wirkstoff-Konjugate (ADCs) und multispezifischer Antikörpertherapeutika für die Onkologie und Immunologie konzentriert, gab heute den erfolgreichen Abschluss seiner Erweiterungsrunden der Serie A bekannt, in denen 47 Millionen US-Dollar aufgebracht wurden. Die Finanzierungsrunde wurde vom bestehenden Investor Legend Capital und dem neuen Investor Meituan Long-Z Investment angeführt, gefolgt von anderen namhaften bestehenden und neuen Investoren wie Lanchi Ventures, Yuanbio Venture Capital, 5Y Capital, Lapam Capital, Runzhang Venture Capital usw.
Vorantreiben der globalen klinischen Entwicklung für zwei führende Wirkstoffe
Die Finanzierungsrunde der Serie A wird dazu beitragen, die globale klinische Entwicklung der beiden führenden Programme des Unternehmens mit deutlichen Wettbewerbsvorteilen voranzutreiben. ALK201, ein potenziell erstklassiges und bestes FGFR2b-gerichtetes ADC, hat bei mehreren Tumorarten vielversprechende Wirksamkeitssignale mit einem günstigen Sicherheitsprofil gezeigt, was seine Entwicklung als Basistherapie für FGFR2b-überexprimierende solide Tumoren unterstützt. Parallel dazu haben erste klinische Daten zu ALK202 vorläufige Hinweise auf das Potenzial des bispezifischen ADC gegen EGFR/cMET als Eckpfeilertherapie bei nicht-kleinzelligem Lungenkrebs geliefert. Darüber hinaus wird das Programm auf die klinische Bewertung einer breiteren Palette von Biomarker-definierten Tumortypen und Patientengruppen ausgeweitet.
AllinkBio hat mit der Entwicklung beider klinischer Leitwirkstoffe begonnen. Dabei verfolgt das Unternehmen eine biomarkerbasierte Strategie, um die Wirksamkeit bei einem breiten Spektrum solider Tumoren nachzuweisen. Kurzfristig plant das Unternehmen die Einleitung von Kombinationsstudien, um das therapeutische Potenzial der beiden Wirkstoffe in einer breiteren Patientengruppe weiter zu untersuchen. Diese Initiativen werden die Vorbereitung von ALK201 und ALK202 für die zulassungsrelevanten Studien beschleunigen und gleichzeitig ein differenziertes Profil in ihren jeweiligen Zielindikationen etablieren.
Erweiterung der Fähigkeiten der Plattform für neuartige Technologien
Über seine ADC-Technologie hinaus etabliert AllinkBio eine proprietäre Plattform für maskierte T-Zell-Engager (TCE), um die Anwendung von TCEs bei soliden Tumoren weiterzuentwickeln. Im Bereich der Immunologie treibt das Unternehmen die Entwicklung eines Portfolios von erstklassigen bi- und multispezifischen Antikörper-Wirkstoffkandidaten voran. Diese Programme basieren auf rationalen biologischen Konzepten und zielen darauf ab, Lösungen der nächsten Generation für Patientengruppen bereitzustellen, die nach den aktuellen Versorgungsstandards unterversorgt sind.
„Wir schätzen die entschlossene und anhaltende Unterstützung unserer Investoren innerhalb eines so kurzen Zeitraums sehr”, erklärte Dr. Hui Feng, Gründer und Chief Executive Officer von AllinkBio. „Mit dieser Unterstützung können wir unseren klaren klinischen Fahrplan zur Beschleunigung unserer Leitprogramme weiterverfolgen. Neben den beiden führenden Programmen ist unsere Forschungsplattform vollständig aktiviert und bereit, eine neue Welle innovativer Medikamentenkandidaten hervorzubringen, die in absehbarer Zukunft weiteren Mehrwert schaffen werden.”
„Unsere anhaltende Unterstützung basiert auf unserem Vertrauen in die effiziente Umsetzung durch das Team von AllinkBio und dessen solide Entwicklungsstrategie”, erklärte Tan Hong, Managing Director bei Legend Capital. „Die rasanten klinischen Fortschritte ihrer beiden wettbewerbsfähigen Leitprodukte bestätigen bereits jetzt die Leistungsfähigkeit der ADC-Plattform des Unternehmens und stellen einen erheblichen Mehrwert dar. Wir freuen uns auf die bevorstehenden klinischen Ergebnisse und darauf, weitere innovative Programme aus ihren Forschungsplattformen hervorgehen zu sehen.”
„Das Team von AllinkBio verbindet eine internationale Denkweise mit erstklassiger Umsetzung und setzt damit bemerkenswerte Maßstäbe im Bereich der Antikörper-Wirkstoff-Konjugate”, erklärte Xuejing Guo, Managing Director und Head of Healthcare bei Meituan Long-Z Investment. „Wir sind tief beeindruckt vom Potenzial ihrer Technologieplattform und freuen uns darauf, dem Team dabei zu unterstützen, diese originellen Innovationen weltweit umzusetzen und damit Patienten auf der ganzen Welt lebensverändernde Therapien anzubieten.”
Information zu AllinkBio
AllinkBio wurde im Jahr 2023 gegründet und ist ein Biotechnologieunternehmen im klinischen Stadium, das sich der Erforschung und Entwicklung differenzierter ADCs und multispezifischer Antikörper für die Onkologie und Immunologie widmet. Dank der Synergie aus innovativen Plattformfähigkeiten und außergewöhnlicher F&E-Effizienz hat das Unternehmen zwei ADC-Kandidaten rasch in globale klinische Phase-I-Studien gebracht. AllinkBio engagiert sich für die Weiterentwicklung von ADC und multispezifischen Antikörpern, um das Leben von Patienten in Not weltweit zu verbessern.
The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with strong backing from both new investors and existing supporters
Proceeds to advance two differentiated and highly competitive ADC programs in global Phase I trials
The financing will support continued development of ADC and multi-specific antibody platforms aimed at addressing critical limitations of existing biologic therapeutics
SHANGHAI, Dec. 16, 2025 — Allink Biotherapeutics, Inc. (AllinkBio), a clinical-stage biotechnology company focusing on developing advanced antibody-drug conjugates (ADCs) and multi-specific antibody therapeutics for oncology and immunology, today announced successful completion of its extension rounds of Series A, raising 47 million US dollars. The extension rounds were led by existing supporter Legend Capital and new investor Meituan Long-Z Investment, followed by other prominent returning and new investors including Lanchi Ventures, Yuanbio Venture Capital, 5Y Capital, Lapam Capital, Runzhang Venture Capital, etc.
Advancing Global Clinical Development for Two Leading Assets
The Series A extension rounds will help advance global clinical development for the company’s two leading programs with distinct competitive advantages. ALK201, a potential first- and best-in-class FGFR2b-targeted ADC, has demonstrated encouraging efficacy signals across multiple tumor types with a favorable safety profile, supporting its development as a backbone therapy for FGFR2b-overexpressing solid tumors. In parallel, early clinical data for ALK202 have provided preliminary support of the EGFR/cMET bispecific ADC’s potential as a cornerstone therapy in non-small cell lung cancer. Furthermore, the program is being expanded into clinical evaluation of a broader range of biomarker-defined tumor types and patient populations.
AllinkBio has started developing both lead clinical assets through a biomarker-guided strategy designed to demonstrate efficacy in a broad spectrum of solid tumors. In the near term, the company plans to initiate combination therapy studies to further explore the two assets’ therapeutic potential in broader front-line patient populations. These initiatives will accelerate ALK201 and ALK202 toward pivotal trial readiness while establishing a differentiated profile in their respective target indications.
Augmenting Novel Technology Platform Capabilities
Expanding beyond its ADC technology, AllinkBio is establishing a proprietary masked T-cell engager (TCE) platform to evolve the application of TCEs for solid tumors. In the immunology space, the company is advancing a portfolio of first-in-class bi- and multi-specific antibody drug candidates. Anchored in rational biology design, these programs aim to deliver next-generation solutions for patient populations underserved by current standards of care.
“We sincerely appreciate the decisive and continued support from our investors within such a short timeframe,” said Hui Feng, Ph.D., Founder and Chief Executive Officer of AllinkBio. “With this support, we are moving forward with a clear clinical roadmap to accelerate our lead programs. Beyond the two leading programs, our discovery engine is fully activated, poised to deliver new wave of innovative drug candidates that will unlock further value in the foreseeable future .”
“Our continued support is rooted in our confidence in the AllinkBio team’s efficient execution and their robust development strategy,” said Tan Hong, Managing Director at Legend Capital. “The rapid clinical advancement of their two competitive lead assets is already serving as a strong validation of the company’s ADC platform and presenting significant value. We look forward to the near-term clinical readouts and seeing more innovative programs emerge from their discovery platforms.”
“The AllinkBio team pairs an international mindset with best-in-class execution, setting a remarkable pace in the ADC space,” said Xuejing Guo, Managing Director and Head of Healthcare at Meituan Long-Z Investment. “We are deeply impressed by the potential of their technology platform and are excited to help the team translate these original innovations into global impact, ultimately delivering life-changing therapies to patients worldwide.”
About AllinkBio
Founded in 2023, AllinkBio is a clinical-stage biotechnology company dedicated to the discovery and development of differentiated ADCs and multi-specific antibodies for oncology and immunology. Leveraging a synergy of innovative platform capabilities and exceptional R&D efficiency, the company has rapidly advanced two ADC candidates into global Phase I clinical trials. AllinkBio is committed to advancing ADC and multi-specific antibody innovation to transform lives for patients in need worldwide.
L’entreprise a obtenu 47 millions de dollars grâce à l’extension de la série A menée par Legend Capital et Meituan Long-Z Investment, avec un fort soutien de la part de nouveaux investisseurs et de soutiens existants.
Des produits destinés à l’avancement de deux programmes de conjugués anticorps-médicaments (ADC) différenciés et hautement compétitifs dans le cadre d’essais de phase I à l’échelle mondiale
Le financement permettra de poursuivre le développement de plateformes ADC et d’anticorps multispécifiques afin de remédier aux limites critiques des thérapies biologiques existantes.
SHANGHAI, 16 décembre 2025 — Allink Biotherapeutics, Inc. (AllinkBio), une société de biotechnologie en phase clinique qui se concentre sur le développement de conjugués anticorps-médicaments (ADC) avancés et de thérapies à base d’anticorps multispécifiques pour l’oncologie et l’immunologie, a annoncé aujourd’hui la conclusion réussi de ses tours de table supplémentaires de la série A pour lever 47 millions de dollars US. Ces tours supplémentaires ont été dirigés par Legend Capital, qui soutient déjà l’entreprise, et par le nouvel investisseur Meituan Long-Z Investment, suivis par d’autres investisseurs importants, anciens et nouveaux, tels que Lanchi Ventures, Yuanbio Venture Capital, 5Y Capital, Lapam Capital, Runzhang Venture Capital, etc.
Avancement du développement clinique mondial de deux produits de premier plan
Les tours supplémentaires de la série A contribueront à faire progresser le développement clinique mondial des deux programmes phares de la société, qui présentent des avantages concurrentiels distincts. ALK201, un ADC ciblant le FGFR2b susceptible d’être le premier et le meilleur de sa catégorie, a démontré des signes d’efficacité encourageants dans plusieurs types de tumeurs avec un profil d’innocuité favorable, ce qui soutient son développement en tant que traitement de base pour les tumeurs solides surexprimant le FGFR2b. Parallèlement, les premières données cliniques concernant ALK202 ont apporté un soutien préliminaire au potentiel de l’ADC bispécifique EGFR/cMET en tant que traitement de base dans le cancer du poumon non à petites cellules. En outre, le programme est étendu à l’évaluation clinique d’un éventail plus large de types de tumeurs et de populations de patients définis par des biomarqueurs.
AllinkBio a commencé à développer les deux produits cliniques principaux par le biais d’une stratégie guidée par les biomarqueurs, conçue pour démontrer l’efficacité dans un large spectre de tumeurs solides. À court terme, la société prévoit de lancer des études de bithérapie afin d’explorer plus avant le potentiel thérapeutique des deux produits dans des populations de patients de première ligne plus larges. Ces initiatives permettront d’accélérer la préparation des essais pivots pour ALK201 et ALK202 tout en établissant un profil différencié dans leurs indications cibles respectives.
Augmenter les capacités des plates-formes de nouvelles technologies
Au-delà de sa technologie ADC, AllinkBio met en place une plateforme propriétaire d’engagement de cellules T masquées (TCE) afin de développer l’application des TCE pour les tumeurs solides. En matière d’immunologie, la société développe un portefeuille de médicaments candidats anticorps bi- et multispécifiques de premier ordre. Ancrés dans une conception biologique rationnelle, ces programmes ont pour objectif de fournir des solutions de nouvelle génération aux populations de patients mal desservies par les normes de soins actuelles.
« Nous apprécions sincèrement le soutien décisif et continu de nos investisseurs dans un délai aussi court », a déclaré Hui Feng, Ph.D., fondateur et directeur général d’AllinkBio. « Grâce à ce soutien, nous avançons avec une feuille de route clinique claire pour accélérer nos principaux programmes. Au-delà des deux programmes phares, notre moteur de découverte est pleinement activé, prêt à fournir une nouvelle vague de médicaments candidats innovants qui génèreront de la valeur supplémentaire dans un avenir prévisible. »
« Notre soutien continu se justifie par notre confiance dans l’efficacité de l’équipe d’AllinkBio et dans sa solide stratégie de développement », a déclaré Tan Hong, directeur général de Legend Capital. « L’avancement clinique rapide de ses deux principaux produits compétitifs constitue déjà une validation solide de la plateforme ADC de la société et présente une valeur significative. Nous attendons avec impatience les résultats cliniques à court terme et nous nous réjouissons de voir d’autres programmes innovants émerger de ses plates-formes de découverte. »
« L’équipe d’AllinkBio associe un état d’esprit international à une exécution de premier ordre, établissant un rythme remarquable dans le domaine des ADC », a déclaré Xuejing Guo, directeur général et responsable des soins de santé chez Meituan Long-Z Investment. « Nous sommes profondément impressionnés par le potentiel de sa plateforme technologique et nous sommes ravis d’aider l’équipe à traduire ces innovations originales en un impact mondial, afin de proposer des traitements qui changeront la vie des patients dans le monde entier. »
À propos d’AllinkBio
Fondée en 2023, AllinkBio est une société de biotechnologie au stade clinique qui se consacre à la découverte et au développement d’ADC différenciés et d’anticorps multispécifiques pour l’oncologie et l’immunologie. En s’appuyant sur une synergie de capacités de plates-formes innovantes et une efficacité exceptionnelle en matière de recherche et développement, l’entreprise a rapidement fait progresser deux candidats ADC vers des essais cliniques mondiaux de phase I. AllinkBio s’engage à faire progresser l’innovation en matière d’ADC et d’anticorps multi-spécifiques afin de transformer la vie des patients dans le monde entier.
SEOUL, South Korea, Dec. 16, 2025 — The Ministry of SMEs and Startups (MSS) and the Korea Startup Forum (KSF) announced that COMEUP 2025, Korea’s flagship global startup festival, successfully concluded after a three-day run from December 10 to 12 at COEX in Seoul.
On-site view of COMEUP 2025
Now in its seventh year, COMEUP 2025 was hosted by the Ministry of SMEs and Startups, overseen by the Korea Institute of Startup & Entrepreneurship Development (KISED), and co-organized by the Korea Startup Forum, the Korea Venture Business Association, and the Korea Venture Capital Association. Held under the slogan “Recode the Future,” this year’s event highlighted how startups are redefining the future of industries through technological innovation and entrepreneurial spirit. Centered on the three core themes of Deep Tech, Global, and Entrepreneurship, COMEUP 2025 featured a wide range of programs including exhibitions, conferences, IR pitching sessions, and open innovation initiatives, further strengthening collaboration and exchange across the global startup ecosystem.
COMEUP 2025 welcomed participants from 46 countries, marking its largest global presence to date. The event brought together a diverse group of startup founders, investors, large enterprises, and government officials from Korea and abroad, creating a highly dynamic environment for exchange and collaboration. In particular, a total of 3,447 investment and business matchmaking meetings were successfully completed through a combination of online matchmaking platforms, pre-arranged 1:1 meetings, and on-site investor booth consultations, earning strong recognition as a practical platform for expanding global business opportunities.
COMEUP 2025 introduced meaningful upgrades across its overall program structure compared to previous years. Conference sessions were reorganized around clearly defined daily themes aligned with the three core pillars of deep tech, global expansion, and entrepreneurship. In line with the festival’s slogan, stages and sessions were designed with a future-oriented approach, significantly enhancing audience engagement.
Another notable change was the first-ever joint organization by the Korea Startup Forum, the Korea Venture Business Association, and the Korea Venture Capital Association, which strengthened collaboration across the private startup ecosystem. This shift led to a stronger focus on inviting global VCs, CVCs, and accelerators, expanding opportunities for concrete investment discussions and strategic partnerships. Pre-arranged and open 1:1 meetings, investor booths, and sessions linked to venture investment briefings played a key role in helping startups secure tangible business opportunities.
Expanded side events also drew strong interest. Programs such as Startup Autobahn Korea 2025, Challenge! K-Startup Grand Finale, TIPS Scale-up Bridge, and a senior venture roundtable enriched the overall program and encouraged broader participation from companies and institutions. Programs designed for the general public were also strengthened, including the COMEUP Docent Tour, a B2C-focused COMEUP Flea Market, and pitch sessions by university startup teams, further broadening public engagement.
One of the most significant achievements of COMEUP 2025 was the expansion of international participation. A total of seven countries, including Saudi Arabia, India, Japan, and Canada, operated national pavilions to showcase their startup ecosystems and technologies. Australia and Sierra Leone joined the festival for the first time, further expanding COMEUP’s global network. Startup ecosystem stakeholders from across continents actively took part in IR pitching, conferences, networking sessions, and exhibitions, significantly increasing the density of global exchange.
Beyond technology trends and global collaboration, COMEUP 2025 placed a strong emphasis on spreading entrepreneurial values across society and industry. Newly introduced this year, the “Future Founder” program spotlighted the next generation of entrepreneurs and aspiring founders. Through student startup presentations, mentoring sessions, and talks by Gen Z founders, the program underscored the importance of nurturing entrepreneurial talent as a foundation for future national competitiveness.
Additional sessions focused on social value creation also garnered attention. These included discussions on climate-tech solutions addressing the climate crisis, trend analysis sessions led by Gen Z entrepreneurs, and talks exploring the life of founders from a family perspective. Major startup competitions such as the COMEUP Stars 2025 Final Pitch, the Challenge! K-Startup 2025 Grand Finale jointly hosted by 10 government ministries, and the K-Startup Grand Challenge (KSGC) Demo Day for foreign startups further highlighted the full spectrum of the startup ecosystem—from early-stage founders to globally scaling ventures.
COMEUP 2025 will be available for on-demand viewing through the festival’s official YouTube channel.
